Timothy Olah

Dr Olah is the Group Director of Bioanalytical Research at Bristol-Myers Squibb Company (NJ, USA) where his research interests center on the development of comprehensive multiple component bioanalytical methods to quantify all types of drug modalities and endogenous proteins and biomarkers in numerous biological fluids. His team integrates intricate sample collection procedures, analyte enrichment techniques, and liquid chromatography mass spectrometry (LC–MS) detection to maximize data generation in in vivo studies. These bioanalytical strategies support all drug discovery programs at BMS and the Biocon-BMS-Research-Center (BBRC) in Bangalore, India.

Dr Olah is a graduate of Princeton University (BA Chemistry; NJ, USA) and the University of Pennsylvania (PhD Biological Chemistry; PA, USA). His career started at Merck Research Laboratories, included time at DuPont Pharmaceuticals, and now has been at BMS for the past 19 years. Dr Olah has over 100 publications and has presented at numerous international universities and conferences throughout his career.

What three things would you take if you were stranded on a desert island?

Binoculars, telescope, writing materials

If you weren’t a bioanalysts what would you be?

College basketball coach

What is your favorite city?

Cape May Point, NJ

Why have you decided to become a Zone Leader?

Promote scientific discussion within the bioanalytical community


Journal articles from Bioanalysis Interviews
Ion suppression and cannulation locking solutions

Analytical considerations for quantitative LC–MS strategies for measuring antibody drug–target engagement in tissues

Optimization of Exactive Orbitrap™ acquisition parameters for quantitative bioanalysis

The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis

Application and challenges in using LC–MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery

Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC–MS method

Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC–MS-based bioanalytical methods in drug discovery

A bioanalytical strategy utilizing dried blood spot sampling and LC–MS/MS in discovery toxicology studies

What is next for dried blood spots?

Immunoaffinity LC–MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker

Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS

Beyond classical derivatization: analyte ‘derivatives’ in the bioanalysis of endogenous and exogenous compounds

LC–MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin

Bioanalysis of (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268) in rat plasma using derivatization liquid chromatography/mass spectrometry

DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors

Pellet digestion: a simple and efficient sample preparation technique for LC–MS/MS quantification of large therapeutic proteins in plasma

Quantification of human mAbs in mouse tissues using generic affinity enrichment procedures and LC–MS detection

Ultrasensitive quantitative LC–MS/MS of an inhibitor of apoptosis protein’s antagonist in plasma using protein target affinity extraction

Quantification of in vivo site-specific Asp isomerization and Asn deamidation of mAbs in animal serum using IP-LC–MS

Antibody–drug conjugate bioanalysis using LB-LC–MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays

2013 White Paper on recent issues in bioanalysis: ‘hybrid’ – the best of LBA and LCMS

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1 – small molecules by LCMS)

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input)

2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 – hybrid LBA/LCMS and input from regulatory agencies)

2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 – Hybrid LBA/LCMS and input from regulatory agencies)

2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity)